Close Menu

NEW YORK (360Dx) – UK diagnostics firm Oncimmune announced today that it has signed on Sabartech as the exclusive distributor of its lung cancer test EarlyCDT-Lung in Portugal.

The test, which was launched in the US in 2012, is designed to measure levels of seven auto-antibodies to tumor-associated antigens. According to Oncimmune, it can detect all forms of lung cancer at any stage.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.